Makes and sells over 500,000 distinct protein research reagents, each individually tested and registered to a specific factory.
At a glance
- Depends onMidstream position: 3 outgoing, 3 incoming connections
- ScaleMarket cap is above the global median
Makes and sells over 500,000 distinct protein research reagents, each individually tested and registered to a specific factory.
What this company is and how it runs — written from structure, not news.
Bio-Techne manufactures and validates over 500,000 individual protein reagents — antibodies, cytokines, growth factors — across facilities in Minneapolis, Bristol, and Shanghai, where each product requires its own distinct expression, purification, and stability testing process before it can ship. Because those validated processes are registered to specific physical sites under ISO 13485 and FDA rules, the same protein cannot legally be made at a different building without repeating the entire qualification from scratch, so the catalog number and the facility are effectively the same asset. Researchers who build a multi-year study around a specific catalog number cannot swap to a competitor's version mid-project without invalidating their experimental controls, which means the switching cost is not a pricing question but a methodological one — the catalog number has become part of the scientific record. The vulnerability that follows from this structure is that a regulatory shutdown or contamination event at Minneapolis or Bristol would strand thousands of registered SKUs with no legal path to move production elsewhere quickly, cutting off supply to studies that have no permissible substitute.
How does this company make money?
The company sells individual protein reagents, antibodies, and diagnostic kits directly to laboratories and through distribution partners, charging per unit. Custom antibody development services bring in higher margins. Instruments sold to laboratories then generate ongoing revenue because those labs keep buying consumables that only work with the instruments they already own.
What makes this company hard to replace?
Researchers who have built multi-year studies around a specific R&D Systems antibody catalog number cannot swap to a different supplier's version mid-project — antibody lots vary between manufacturers, and any change would invalidate their experimental controls and force them to revalidate everything from the beginning. Pathology laboratories using Advanced Cell Diagnostics spatial biology assays would need to retrain their technicians and revalidate their protocols on a completely different platform. Pharmaceutical R&D departments have the specific catalog numbers written into their standard operating procedures, making a switch a documentation and compliance problem, not just a purchasing one.
What limits this company?
Every new product requires its own individual round of biological testing — its own growth conditions, its own purification run, its own stability checks. None of that can be standardized or run in parallel across the catalog. That per-product requirement caps how fast new products can be added and makes it very slow to move production of any single product to a different facility when something goes wrong.
What does this company depend on?
The company cannot operate without recombinant protein expression systems used to produce cytokines and growth factors, cold storage facilities in Minneapolis and at international distribution centers, dry ice supply chains that keep proteins at the right temperature during shipping, ISO 13485 and FDA registration to sell diagnostic products, and academic institution partnerships that support custom antibody development.
Who depends on this company?
Pharmaceutical companies running drug discovery programs depend on the validated research antibodies to identify targets and study how drugs work — losing access would stall those programs. Academic research labs would face delays whenever a substitute reagent required lengthy revalidation before it could be used. Clinical diagnostic laboratories using Advanced Cell Diagnostics spatial biology products would need to reprocess tissue samples on entirely different in-situ hybridization platforms if supply stopped.
How does this company scale?
The digital catalog and automated order systems can handle the full 500,000+ product range without much added cost, giving the company global reach without proportionally more staff. What does not get cheaper or faster as the company grows is the biological manufacturing and quality testing — each product still needs its own distinct process, and no amount of growth changes that.
What external forces can significantly affect this company?
NIH funding cycles and European research grants directly shape how much academic labs spend on protein reagents and instruments, so a budget cut in Washington or Brussels shows up quickly in sales. Post-Brexit rules have split the regulatory requirements for diagnostic products made in Bristol — the company now has to satisfy both UK MHRA and EU MDR standards separately. Chinese import restrictions on biological materials put the Shanghai manufacturing operation at risk of losing access to key inputs.
Where is this company structurally vulnerable?
If a regulatory shutdown or a serious contamination event hit Minneapolis or Bristol, thousands of products registered to those sites could no longer be legally manufactured there. Moving them to another building would require repeating the full qualification process for each one. In the meantime, researchers running multi-year studies on those catalog numbers would have no permitted substitute to switch to.
Price is read as structure — trend, levels, range, peak and volatility drawn on the chart. It does not predict where price goes next.
Sign in to view price data.
Sign in4 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow is this stock behaving?
Three observations describe the present configuration: the fast moving average sits below the slow moving average, the company has been profitable for three years, and cash-flow margin is elevated.
Two structural conditions align: (1) a multi-year price band exists where the stock has, on at least two separated occasions, stopped advancing and pulled back, and (2) current price is back inside or just below that zone, near the top of its recent trading range. The retest is happening at a level the stock has reached before and turned away from.
Three observations describe the present configuration: a high share of the trailing year's weekly closes were higher than the prior week, the company has reported positive net income in each of the last three annual periods, and the industry-benchmarked TTM operating cash flow margin is in the upper peer range.
Current close sits in the upper portion of the 14-week high-low range; current close sits in the upper portion of its 20-week Bollinger Bands; RSI sits above its 20-week recent mean (Bollinger %B applied to RSI).
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
What the company actually pays, and whether its own cash supports it.
The reported statements, read against the company's own industry.
3 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Equity position looks solid, but the composition deserves a look. Equity ratio is elevated for its industry while goodwill is a large share of total assets and large relative to shareholders equity. The equity cushion sits substantially on acquisition-premium book value rather than on retained earnings or paid-in capital.
Three observations have aligned: most-recent-quarter total cash is in the upper portion of its mapped range against most-recent-quarter total debt, EBITDA-to-total-liabilities is in the upper portion of its mapped range, and FCF-to-total-liabilities is in the upper portion of its mapped range.
How is this stock valued?
Retained earnings are a large share of total assets; net income was positive in each of the last 5 fiscal years; shareholders' equity is in the upper part of its industry's equity-to-assets range.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Companies that share the same coordination system — how they create, deliver, or capture value.
Companies that share active interpretations — structural patterns currently present in both stocks.
CompanyGraph